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DVL regulation of tissue-specific aromatase transcripts in breast 
cancer
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News on: DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells by 
Castro-Piedras et al. Oncotarget. 2018; 9:35639-35654. https://doi.org/10.18632/oncotarget.26257
Breast cancer is the most common cancer in women 
in the United States. The majority of breast cancers are 
hormone receptor positive, with around 70% expressing 
the estrogen receptor (ER) and progesterone receptor 
[1]. Excessive estrogen exposure is a well-known risk 
factor for breast cancer and drives increased proliferation 
of ER+ tumors. Aromatase is a cytochrome P450 class 
monooxygenase enzyme that converts androgens to 
estrogens. The increased activity of aromatase enzymes 
has long been associated with tumorigenesis as well 
as other diseases caused by elevated estrogen levels. 
Aromatase activity has also been found in cancers not 
normally connected to hormone dependency. To target 
the reliance of tumors on estrogen, aromatase inhibitors 
such as anastrozole, letrozole, and exemestane are used 
to treat post-menopausal women with ER+ breast cancer 
[1]. Treatment with aromatase inhibitors results in reduced 
estrogen levels in blood and plasma and has significantly 
reduced recurrence of breast cancer in these patients. 
CYP19A1 is the gene that encodes the aromatase enzyme 
making understanding its regulation important to the study 
of cancer and other hormone-related diseases. 
In a recent publication Castro-Piedras et al. set 
out to further understand the transcriptional regulation 
of CYP19A1 in breast cancer cells [2]. The 5’ UTR of 
CYP19A1 contains ten identified alternative untranslated 
first exons that are regulated by tissue-specific promoters 
for the placenta, adipose tissue, brain, skin, bone, and 
gonads [3]. Each tissue-specific isoform has identical 
coding regions but different 5’ untranslated first exons. 
The tissue-specific promoters are regulated by different 
transcription factors and affected by local hormones 
and signaling events. This differential regulation results 
in tissue-specific aromatase expression and estrogen 
biosynthesis. In breast cancer in postmenopausal 
women estrogen can be synthesized by the tumor 
tissue, surrounding stroma, or other body sites such as 
subcutaneous adipose tissue. Furthermore, in tumors 
CYP19A1 transcription loses tissue-specific regulation 
and can be driven by multiple promoters. The interaction 
between malignant epithelial cells and the cells in the 
microenvironment increases aromatase expression from 
multiple promoters resulting in high estrogen production 
in the area surrounding the tumor.
Sirtuin-1 (SIRT1) is a lysine deacetylase that has 
been implicated in aberrant gene silencing in cancer cells 
[4, 5]. In previous work the Pruitt group demonstrated that 
SIRT1 regulates CYP19A1 expression in breast cancer 
cells and that SIRT1, β-catenin and Dishevelled (DVL) 
coregulate Wnt signaling [6, 7]. Wnt pathway signaling is 
critical for development and tissue homeostasis but also 
becomes dysregulated in many different cancer types, 
including breast. DVL proteins are mediators of Wnt 
signaling that integrate cues from many Wnt ligands, 
receptors and co-receptors. The canonical role of DVL is 
in the cytoplasm where it promotes β-catenin stabilization. 
However, several recent studies have demonstrated that 
DVL can translocate to the nucleus, interact with c-Jun 
and β-catenin, and bind to the promoters of Wnt target 
genes [8]. 
This background knowledge led Castro-Piedras et 
al. to hypothesize that nuclear DVL regulates CYP19A1 
expression in breast cancer cells. Using a panel of breast 
cancer cell lines that represent ER+ and ER- types they 
found that breast cancer cells express several different 
CYP19A1 transcripts, including ovary, adipose and 
placental transcripts [2]. Their study mainly focused on 
the less well-understood placental pI.1 transcript because 
it along with pII have been shown to corelate best with 
protein expression and therefore may have the most 
biologically relevant effect on tumor progression. They 
examined two isoforms of DVL, DVL-1 and DVL-3, 
which are localized to the nucleus to varying degrees in 
the breast cancer cell lines. Interestingly, they found that 
DVL-1 and DVL-3 occupy multiple active and inactive 
CYP19A1 promoters. Knockdown of DVL1 or DVL3 
altered expression of different isoforms of CYP19A1 in 
both ER+ and ER- cell lines. Ultimately what is important 
for the biological effect of this transcriptional regulation 
is its effect on estrogen production. DVL3 knockdown 
trended to cause reduced levels of aromatase protein 
and significantly reduced estrogen levels and cellular 
proliferation. Altogether these results suggest that DVL 
isoforms differentially regulate expression of multiple 
tissue-specific CYP19A1 transcripts whose expression is 
dysregulated in breast cancers. 
As a steroid hormone estrogen controls many 
normal aspects of human health such as glucose and 
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lipid homeostasis, bone metabolism and brain function. 
Depletion of estrogen can lead to digestive issues, 
osteoporosis and cognitive problems. While aromatase 
inhibitors have been used successfully to treat breast 
cancer in postmenopausal women, they reduce aromatase 
activity in all tissues throughout the body causing side 
effects related to estrogen deficiency, including bone 
fracture, osteoporosis, and abnormal lipid metabolism 
[9]. Thus, understanding how tissue specific isoforms of 
CYP19A1 expression are regulated in normal cells and 
dysregulated in cancer cells is instrumental in refining 
treatment strategies to reduce unwanted side effects. The 
findings from this study provide the first evidence that 
DVL proteins participate in the regulation of transcription 
of tissue-specific aromatase transcripts [2]. Additional 
work is needed to further elucidate how signaling 
pathways altered in tumors can be targeted to reduce 
expression of CYP19A1 specifically in the tumor and its 
microenvironment while preserving expression in normal 
tissues.
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